New insider activity at Lemaitre Vascular ( (LMAT) ) has taken place on August 13, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
In recent transactions involving Lemaitre Vascular stock, Director Bridget A Ross sold 2,500 shares for a total of $235,000. Meanwhile, Director John Roush sold 7,500 shares, amounting to $694,980. Additionally, President and Director David B. Roberts sold 10,815 shares, generating $999,123 from the sale.
Recent Updates on LMAT stock
Lemaitre Vascular’s recent Q2 earnings call highlighted a positive performance with a 15% increase in sales and a 16% rise in EPS, driven by strong product launches and sales growth in regions like EMEA. The successful launch of Artegraft and an increased sales representative workforce are key contributors to this growth. Despite challenges such as a catheter recall and increased operating expenses, the company raised its full-year revenue guidance to $251 million, reflecting confidence in its financial trajectory. Analyst Michael Petusky upgraded Lemaitre to Outperform, citing the company’s strong Q2 results and expectations for continued growth in the latter half of 2025 and into 2026.
Spark’s Take on LMAT Stock
According to Spark, TipRanks’ AI Analyst, LMAT is a Outperform.
Lemaitre Vascular’s strong financial performance and positive earnings call are the most significant factors driving the stock’s score. The company’s robust growth and profitability metrics, along with a positive outlook, are key strengths. However, the high valuation and overbought technical indicators present potential risks.
To see Spark’s full report on LMAT stock, click here.
More about Lemaitre Vascular
YTD Price Performance: 2.93%
Average Trading Volume: 158,329
Technical Sentiment Signal: Strong Buy
Current Market Cap: $2.14B